RxDoctor Payments Data

Alexandra Weiss, MD

Internal Medicine · Philadelphia, PANPI 1043659774

Payments from drug & device makers

$118,557in general payments, 2019–2025

Across 17 payments — averaging $6973.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$80K
  • AbbVie$38K
  • E.r. Squibb & Sons, L.L.C.$94
  • Revance Therapeutics, Inc.$62
  • Lilly USA, LLC$53
  • Takeda Pharmaceuticals U.S.A., Inc.$36
  • plus $45 from 2 others

What the payments were for

  • Grants$80,00099%
  • Food & beverage$5431%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$118,557 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$43,211
Medicare patients
169
Services billed
413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab70$1,841,344
Humira(Cf) PenAdalimumab55$868,628
Humira PenAdalimumab13$185,273
Cimzia (2 Pack)Certolizumab Pegol13$70,217
Infliximab11$33,125
Budesonide ErBudesonide11$16,944
Mesalamine33$15,289
LinzessLinaclotide13$10,538
Colestipol Hcl40$4,774
CholestyramineCholestyramine (With Sugar)19$2,217
Ondansetron Hcl15$1,864
Esomeprazole Magnesium15$978
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine16$934
Omeprazole76$934
Mesalamine ErMesalamine17$905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$38,145$10,53813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →